-
J Clin Invest: MEK inhibitor cobimetinib combined with PD-L1 inhibitor atezolizumab prolongs PFS in biliary tract cancer (BTC)
Time of Update: 2022-01-23
The study showed that atezolizumab + cobimetinib combination therapy prolonged PFS compared with atezolizumab monotherapy, but the low response rates in both groups also indicated the immune- tolerant properties of BTC .
-
Int J Urol: Which is better between percutaneous ablation and minimally invasive partial nephrectomy in the treatment of cT1a renal tumors?
Time of Update: 2022-01-23
Recently, researchers from Italy published an article in the journal Int J Urol comparing the oncological outcomes of partial nephrectomy and local tumor ablation in patients with T1 renal masses .
-
Liver Cancer: Real-World Efficacy of Lenvatinib in Hepatocellular Carcinoma: A Retrospective Multicenter Study (ELEVATOR)
Time of Update: 2022-01-23
Lenvatinib showed a higher response rate in patients with better liver function (ORR ALBI grade 1: 31.
Lenvatinib showed a higher response rate in patients with better liver function (ORR ALBI grade 1: 31.
-
Ther Adv Med Oncol: A domestic multicenter head-to-head phase III study found that the second-line FOLFIRI regimen was not superior to single-agent irinotecan therapy in patients with metastatic colorectal cancer, but increased toxicity
Time of Update: 2022-01-23
The study is the first head-to-head study and found that second-line single-agent irinotecan achieved similar PFS, OS and ORR as FOLFIRI in patients with mCRC who failed first-line XELOX/FOLFOX regimens, with less toxicity .
-
BMC Cancer: Eribulin improves overall survival after initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer
Time of Update: 2022-01-23
Studies have shown that Eribulin improves overall survival after the initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer .
Studies have shown that Eribulin improves overall survival after the initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer .
-
Bosn J Basic Med Sci: Beware of Chronic Mechanical Stimulation, May Induce Oral Squamous Cell Carcinoma!
Time of Update: 2022-01-23
A study published in Bosn J Basic Med Sci qualitatively and quantitatively reviewed the relationship between chronic mechanical stimulation and OSCC .
, Chronic mechanical irritation and oral squamous cell carcinoma: A systematic review and meta-analysis .
-
Cell Reports: Nanoparticle-assisted CRISPR gene editing of vascular endothelium for the first time
Time of Update: 2022-01-23
On January 4, 2022, You-Yang Zhao's team at Northwestern University Feinberg School of Medicine published a paper entitled: Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA in Cell Reports, a sub-journal of Cell.
-
NEJM: Should patients with untreated advanced melanoma be treated with riralimumab-nivolumab combination or nivolumab alone?
Time of Update: 2022-01-23
In patients with previously untreated metastatic or unresectable melanoma, inhibition of the two immune checkpoints, LAG-3 and PD-1, resulted in a greater benefit in progression-free survival than inhibition of PD-1 alone .
-
Int J Urol: Impact of neoadjuvant chemotherapy on survival and recurrence patterns in patients after robotic-assisted radical cystectomy
Time of Update: 2022-01-23
A Phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OS A phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OSRecently, researchers from the United States published an article in "Int J Urol" to analyze the effect of neoadjuvant chemotherapy on the survival and recurrence patterns of patients with muscle-invasive bladder cancer after robotic-assisted radical cystectomy .
-
Eur J Cancer: Efficacy of abiraterone acetate combined with prednisone (AA+P) in the treatment of metastatic castration-sensitive prostate cancer (mCSPC) patients with visceral metastasis (VM)
Time of Update: 2022-01-23
To evaluate the overall survival (OS) and imaging progression-free survival (rPFS) of abiraterone acetate combined with prednisone (AA+P) in metastatic castration-sensitive prostate cancer (mCSPC) patients with visceral metastasis (VM) influence .
-
Nature Chemical Biology: Crazy Idea: Arming CAR-T Cells to Become a 'Micro Pharmacy' for Cancer Drugs
Time of Update: 2022-01-23
Scheinberg, corresponding author of the study, said: "We call the engineered cells SEAKER cells, SEAKER stands for Synthetic Enzyme-Armed KillER cells, which not only enhance the targeting ability of CAR-T cells, but also combine local Effective small molecule anticancer drugs minimize accidental injury and achieve dual effects .
-
NEJM: The fastest ever!
Time of Update: 2022-01-23
A research team has developed a new ultra-fast genome sequencing method for diagnosing rare genetic diseases that takes an average of 8 hours, unprecedented in standard clinical care .
-
This technology enables scar-free breast reconstruction and restores the feeling of the breast area!
Time of Update: 2022-01-23
The aim of this study is to propose a breast reconstruction method that utilizes the principles of power-assisted liposuction and lipofilling (PALL) for breast matrix separation by infiltration, tunnelling, extensive destruction and fat augmentation, combined with ring (PALLL) Recruit a vascularized flap to reshape the breast .
-
JAHA: "Viagra" also has shortcomings!
Time of Update: 2022-01-23
Finally, compared with the blank control group, the pMLC staining signal in the medial lesion area of the AAA group was significantly reduced, indicating that sildenafil can reduce aortic SMC contractility by inhibiting MLC phosphorylation .
-
Oral Dis: Measuring LDH in saliva can be a useful method for screening for oral cancer and potentially malignant diseases of the oral cavity
Time of Update: 2022-01-23
A study published in Oral Dis evaluated whether salivary lactate dehydrogenase (LDH) levels were increased in patients with oral cancer (OC) or underlying oral malignancy (OPMD) compared with healthy controls (CG) .
-
The fertility hope of gynecological cancer patients, you need to know these
Time of Update: 2022-01-23
In recent years, with the younger age of onset of malignant tumors and the general postponement of the reproductive age of women, fertility protection has become a difficult problem that often needs to be weighed and solved when clinically formulating treatment plans for cancer patients .
-
Eur Urol Focus: Is urodynamics required to screen suitable candidates for prostate surgery with lower urinary tract symptoms?
Time of Update: 2022-01-23
In an exploratory analysis of the UPSTREAM trial, researchers from the United Kingdom, published in the journal Eur Urol Focus , investigated routine diagnostic and urodynamic measurements associated with treatment decisions and outcomes .
-
Front Oncol: Differences in clinical characteristics and clinical prognosis of patients with non-metastatic non-clear cell renal cell carcinoma (non-ccRCC)
Time of Update: 2022-01-23
Non-clear cell renal cell carcinoma (non-ccRCC) includes histologically and molecularly distinct subtypes, such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence of 20% to 25% .
-
Science Immunology: Peng Hua/Fu Yangxin collaborate to develop a new generation of high-efficiency, low-toxicity tumor-specific IL-12 prodrugs
Time of Update: 2022-01-23
On January 7, 2022, Peng Hua's team from the Institute of Biophysics, Chinese Academy of Sciences and Fu Yangxin's team from the University of Texas Southwestern Medical Center published a paper entitled: A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells in the journal Science Immunology Research paper to control established tumors .
-
JAMA Dermatol: Prevalence, incidence and cancer risk in patients with psoriasis and psoriatic arthritis
Time of Update: 2022-01-23
A study published today in JAMA Dermatol assessed cancer associations and risk in patients with psoriasis or psoriatic arthritis, including the risk of specific cancer subtypes .
The primary outcome was cancer (overall and specific subtypes), as measured by cancer prevalence, incidence, and risk estimates in patients with psoriasis or psoriatic arthritis .